MRG 106

Drug Profile

MRG 106

Alternative Names: MRG 106

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator miRagen Therapeutics
  • Class Antifungals; Antineoplastics
  • Mechanism of Action MicroRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Mycosis fungoides
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cutaneous T cell lymphoma
  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 05 Jun 2017 Interim safety and efficacy data from a phase I trial in Cutaneous T-cell lymphoma released by miRagen Therapeutics
  • 24 May 2017 MRG 106 receives Orphan Drug status for Cutaneous T-cell lymphoma in European Union
  • 31 Mar 2017 MRG 106 receives Orphan Drug status for Mycosis fungoides subtype in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top